RT Journal Article
T1 Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT.
A1 DeFilipp, Zachariah
A1 Duarte, Rafael F
A1 Snowden, John A
A1 Majhail, Navneet S
A1 Greenfield, Diana M
A1 Miranda, Jose Lopez
A1 Arat, Mutlu
A1 Baker, K Scott
A1 Burns, Linda J
A1 Duncan, Christine N
A1 Gilleece, Maria
A1 Hale, Gregory A
A1 Hamadani, Mehdi
A1 Hamilton, Betty K
A1 Hogan, William J
A1 Hsu, Jack W
A1 Inamoto, Yoshihiro
A1 Kamble, Rammurti T
A1 Lupo-Stanghellini, Maria Teresa
A1 Malone, Adriana K
A1 McCarthy, Philip
A1 Mohty, Mohamad
A1 Norkin, Maxim
A1 Paplham, Pamela
A1 Ramanathan, Muthalagu
A1 Richart, John M
A1 Salooja, Nina
A1 Schouten, Harry C
A1 Schoemans, Helene
A1 Seber, Adriana
A1 Steinberg, Amir
A1 Wirk, Baldeep M
A1 Wood, William A
A1 Battiwalla, Minoo
A1 Flowers, Mary E D
A1 Savani, Bipin N
A1 Shaw, Bronwen E
K1 Cardiovascular disease
K1 Hematopoietic cell transplantation
K1 Late effects
K1 Metabolic syndrome
K1 Survivorship
AB Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus, and all-cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with an estimated prevalence of MetS of 31% to 49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal to review literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors.
YR 2016
FD 2016-05-14
LK http://hdl.handle.net/10668/10090
UL http://hdl.handle.net/10668/10090
LA en
NO DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, et al. Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. Biol Blood Marrow Transplant. 2016 Aug;22(8):1493-1503
DS RISalud
RD Apr 7, 2025